Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2025Future Journal of Pharmaceutical SciencesOpen Access

Advancing EGFR-targeted anticancer strategies: the potential of thiazole, pyrazole, and thiazole–pyrazole hybrids

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPrerana SanasTCTrupti S. Chitre

Discussion

Loading...

Member takes

Overview

This review highlights thiazole and pyrazole derivatives as potential EGFR-TKIs, suggesting innovative therapeutic options.

Key Points

  • Novel thiazole and pyrazole hybrids show promise as selective EGFR inhibitors for cancer treatment.
  • Potent compounds exhibited submicromolar IC₅₀ values against EGFR, indicating strong bioactivity.
  • Analysis of structure–activity relationships informs the design of more effective hybrid anticancer agents.
  • Computational modeling supports the favorable binding characteristics of these hybrids in EGFR's active site.

Cite This Study

Sanas et al. (2025) studied this question.

synapsesocial.com/papers/68e861907ef2f04ca37e3d45https://doi.org/10.1186/s43094-025-00893-5
View Full Paper
Ask AI
Bookmark
Share